Adverum Biotechnologies

OverviewSuggest Edit

Adverum Biotechnologies (formerly known as Avalanche Biotechnologies) is a clinical-stage gene therapy company targeting unmet medical need in ophthalmology and rare diseases. It develops gene therapy product candidates designed to provide durable efficacy by inducing sustained expression of a therapeutic protein. The company is leveraging its next-generation adeno-associated virus (AAV)-based directed evolution platform to engineer AAV capsids with enhanced tropism for certain tissues and improved antibody neutralization profiles over existing AAV variants.
TypePublic
Founded2006
HQRedwood City, CA, US
Websiteadverum.com
Employee Ratings3.9

Latest Updates

Employees (est.) (Feb 2020)114(+19%)
Job Openings14
Revenue (FY, 2020)$0(-100%)
Share Price (Sept 2021)$2.3(+2%)
Cybersecurity ratingBMore

Key People/Management at Adverum Biotechnologies

Laurent Fischer

Laurent Fischer

Chief Executive Officer
Leone Patterson

Leone Patterson

President and Chief Financial Officer
Thomas Leung

Thomas Leung

Chief Financial Officer
Christopher J. Derespino

Christopher J. Derespino

Chief Business Officer
Julie Clark

Julie Clark

Chief Medical Officer
Peter Soparkar

Peter Soparkar

Chief Legal Officer
Show more

Adverum Biotechnologies Office Locations

Adverum Biotechnologies has offices in Redwood City and Philadelphia
Redwood City, CA, US (HQ)
800 Saginaw Dr
Philadelphia, PA, US
Philadelphia, PA, USA
Show all (2)

Adverum Biotechnologies Financials and Metrics

Adverum Biotechnologies Revenue

USD

Revenue (Q1, 2021)

7.5m

Net income (Q1, 2021)

(28.4m)

EBIT (Q1, 2021)

(28.6m)

Market capitalization (23-Sept-2021)

220.8m

Closing stock price (23-Sept-2021)

2.3

Cash (31-Mar-2021)

45.4m

EV

205.6m
Adverum Biotechnologies's current market capitalization is $220.8 m.
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Revenue

572.0k2.3m1.6m250.0k

Revenue growth, %

305%(37%)

Cost of goods sold

100.0k

Gross profit

1.5m
Quarterly
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Revenue

135.0k204.0k493.0k833.0k250.0k7.5m

General and administrative expense

1.5m2.4m4.1m5.0m7.6m8.3m5.1m6.1m8.0m4.1m4.8m5.4m9.2m4.8m5.6m7.1m7.4m9.0m10.6m11.4m16.2m

R&D expense

3.1m5.7m5.6m5.1m7.5m7.5m8.0m8.4m9.1m8.5m10.3m12.8m11.2m14.5m10.1m9.0m9.9m14.8m19.2m16.7m20.0m

Operating expense total

4.6m8.1m9.8m10.1m15.2m15.8m13.1m14.5m17.1m12.6m15.0m18.2m20.4m19.3m15.7m16.1m17.3m23.8m29.8m28.0m36.1m
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Cash

159.4m221.3m222.2m70.5m154.9m65.9m62.4m

Prepaid Expenses

3.3m3.7m9.8m4.7m

Inventories

874.0k1.5m2.2m

Current Assets

160.3m261.0m225.3m193.7m208.8m175.9m434.4m
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Net Income

(25.4m)(47.5m)(113.7m)(56.1m)(72.6m)(64.5m)(117.5m)

Depreciation and Amortization

162.0k812.0k1.6m2.1m1.8m1.6m4.2m

Inventories

(624.0k)(531.0k)71.0k

Accounts Payable

(6.0k)18.2m(111.0k)333.0k(67.0k)(650.0k)1.6m
USDQ2, 2014

Financial Leverage

-3.3 x
Show all financial metrics

Adverum Biotechnologies Operating Metrics

FY, 2016

Patents Issued

12

Patents Pending

60
Show all operating metrics

Adverum Biotechnologies Cybersecurity Score

Cybersecurity ratingPremium dataset

B

81/100

SecurityScorecard logo

Adverum Biotechnologies Online and Social Media Presence

Embed Graph

Adverum Biotechnologies News and Updates

The Sonic Fund II, L.P. Files Preliminary Proxy Statement Relating to the Election of Highly Qualified Independent Directors at the 2021 Annual Meeting of Adverum Biotechnologies, Inc.

HONOLULU, April 8, 2021 /PRNewswire/ -- The Sonic Fund II, L.P. ("Sonic"), which beneficially owns approximately 6.7% of the outstanding common stock of Adverum Biotechnologies, Inc. (NASDAQ: ADVM) (the "Company" or "Adverum"), announced today that it has filed a preliminary proxy...

Adverum Biotechnologies Completes Patient Enrollment for INFINITY Phase 2 Trial of ADVM-022 in DME and Provides 2021 Business Outlook

-- INFINITY Phase 2 trial fully enrolled; data expected in 2H21 -- -- First pivotal trial planned for ADVM-022 in wet AMD in mid-2021; regulatory agency discussion planned 1Q21 --

Adverum Biotechnologies to Present at 39th Annual J.P. Morgan Healthcare Conference

REDWOOD CITY, Calif., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced the company’s presentation at the 39th Annual J.P. Morgan Healthcare Conference on …

Adverum Biotechnologies Appoints Pharmaceutical Industry Veteran Dawn Svoronos to Board of Directors

REDWOOD CITY, Calif., Dec. 14, 2020 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced the appointment of Dawn Svoronos as an independent member of Adverum’s Board of Dir…

Adverum Biotechnologies Presents at the Piper Sandler Annual Virtual Healthcare Conference

REDWOOD CITY, Calif., Nov. 23, 2020 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced the company’s presentation at the Piper Sandler 32nd Annual Virtual Healthcare Conf…

Adverum Biotechnologies Announces Positive Interim Data from Cohorts 1-4 from OPTIC Phase 1 Trial of ADVM-022 Intravitreal Gene Therapy for Wet AMD

-- Maintained efficacy and greatly reduced anti-VEGF treatment burden after a single IVT injection of ADVM-022 -- -- Robust preliminary aqueous anti-VEGF protein expression observed at 18 months in Cohort 1 –
Show more

Adverum Biotechnologies Blogs

Adverum Provides Update on ADVM-022 and the INFINITY Trial in Patients with Diabetic Macular Edema

-- Based on latest analyses, company is revising ADVM-022 development plan to focus on  wet AMD and low doses (2 x 10^11 vg/eye and lower);  no longer planning development for DME -- -- Company to host conference call and webcast today at 1:30 pm PT / 4:30 pm ET -- REDWOOD CITY, Calif., July 22,

Adverum Announces Changes to Management Team

-- Christopher J. DeRespino appointed acting CFO -- -- Peter Soparkar appointed COO -- -- Leone Patterson departs as president and CFO after five years of service -- REDWOOD CITY, Calif., June 24, 2021 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc.

Adverum Biotechnologies Provides Update on the INFINITY Trial Evaluating ADVM-022 in Patients with Diabetic Macular Edema

REDWOOD CITY, Calif., April 28, 2021 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM) announced a Suspected Unexpected Serious Adverse Reaction (SUSAR) of hypotony (clinically-relevant decrease in ocular pressure) in its INFINITY clinical trial evaluating ADVM-022 gene therapy for

Adverum Files Investor Presentation Highlighting Significant Strategic Progress and Purpose-Built Board to Oversee Stockholder Value Creation

Adverum Files Investor Presentation Highlighting Significant Strategic Progress and Purpose-Built Board to Oversee Stockholder Value Creation Content Import Thu, 04/22/2021 - 16:15 Adverum Files Investor Presentation Highlighting Significant Strategic Progress and Purpose-Built Board to Ov…

Adverum Announces Senior Appointments for Patient Access and Clinical Operations as ADVM-022 Advances Toward Global Phase 3 Trials

-- Anand Reddi appointed vice president, patient advocacy, access, and  digital innovation -- -- Bill Tan, PharmD, appointed vice president,  clinical operations program lead -- REDWOOD CITY, Calif., March 30, 2021 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc.

Adverum Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

REDWOOD CITY, Calif., March 18, 2021 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced a grant of stock options to a new employee.
Show more

Adverum Biotechnologies Frequently Asked Questions

  • When was Adverum Biotechnologies founded?

    Adverum Biotechnologies was founded in 2006.

  • Who are Adverum Biotechnologies key executives?

    Adverum Biotechnologies's key executives are Laurent Fischer, Leone Patterson and Thomas Leung.

  • How many employees does Adverum Biotechnologies have?

    Adverum Biotechnologies has 114 employees.

  • Who are Adverum Biotechnologies competitors?

    Competitors of Adverum Biotechnologies include Marsala Biotech, Neuren Pharmaceuticals and Synchronicity Pharma.

  • Where is Adverum Biotechnologies headquarters?

    Adverum Biotechnologies headquarters is located at 800 Saginaw Dr, Redwood City.

  • Where are Adverum Biotechnologies offices?

    Adverum Biotechnologies has offices in Redwood City and Philadelphia.

  • How many offices does Adverum Biotechnologies have?

    Adverum Biotechnologies has 2 offices.